Cargando…

Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group

The 3rd Cardiovascular Outcome Trial Summit of the Diabetes & Cardiovascular Disease EASD Study Group was held on the 26–27 October 2017 in Munich. As in 2015 and 2016, this summit was organised in light of recently completed and published CVOTs on diabetes, aiming to serve as a reference meetin...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnell, Oliver, Standl, Eberhard, Catrinoiu, Doina, Genovese, Stefano, Lalic, Nebojsa, Lalic, Katarina, Skrha, Jan, Valensi, Paul, Ceriello, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819256/
https://www.ncbi.nlm.nih.gov/pubmed/29458368
http://dx.doi.org/10.1186/s12933-018-0667-2
_version_ 1783301177691078656
author Schnell, Oliver
Standl, Eberhard
Catrinoiu, Doina
Genovese, Stefano
Lalic, Nebojsa
Lalic, Katarina
Skrha, Jan
Valensi, Paul
Ceriello, Antonio
author_facet Schnell, Oliver
Standl, Eberhard
Catrinoiu, Doina
Genovese, Stefano
Lalic, Nebojsa
Lalic, Katarina
Skrha, Jan
Valensi, Paul
Ceriello, Antonio
author_sort Schnell, Oliver
collection PubMed
description The 3rd Cardiovascular Outcome Trial Summit of the Diabetes & Cardiovascular Disease EASD Study Group was held on the 26–27 October 2017 in Munich. As in 2015 and 2016, this summit was organised in light of recently completed and published CVOTs on diabetes, aiming to serve as a reference meeting for in-depth discussions on the topic. Amongst others, the CVOTs EXSCEL, DEVOTE, the CANVAS program and the ACE-trial, which released primary outcome results in 2017, were discussed. Trial implications for diabetes management and recent perspectives of diabetologists, cardiologists, endocrinologists, nephrologists and general practitioners were highlighted. The clinical relevance of cardiovascular outcome trials and its implications regarding reimbursement were compared with real-world studies. The 4th Cardiovascular Outcome Trial Summit will be held in Munich 25–26 October 2018 (http://www.dcvd.org).
format Online
Article
Text
id pubmed-5819256
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-58192562018-02-21 Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group Schnell, Oliver Standl, Eberhard Catrinoiu, Doina Genovese, Stefano Lalic, Nebojsa Lalic, Katarina Skrha, Jan Valensi, Paul Ceriello, Antonio Cardiovasc Diabetol Commentary The 3rd Cardiovascular Outcome Trial Summit of the Diabetes & Cardiovascular Disease EASD Study Group was held on the 26–27 October 2017 in Munich. As in 2015 and 2016, this summit was organised in light of recently completed and published CVOTs on diabetes, aiming to serve as a reference meeting for in-depth discussions on the topic. Amongst others, the CVOTs EXSCEL, DEVOTE, the CANVAS program and the ACE-trial, which released primary outcome results in 2017, were discussed. Trial implications for diabetes management and recent perspectives of diabetologists, cardiologists, endocrinologists, nephrologists and general practitioners were highlighted. The clinical relevance of cardiovascular outcome trials and its implications regarding reimbursement were compared with real-world studies. The 4th Cardiovascular Outcome Trial Summit will be held in Munich 25–26 October 2018 (http://www.dcvd.org). BioMed Central 2018-02-19 /pmc/articles/PMC5819256/ /pubmed/29458368 http://dx.doi.org/10.1186/s12933-018-0667-2 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Schnell, Oliver
Standl, Eberhard
Catrinoiu, Doina
Genovese, Stefano
Lalic, Nebojsa
Lalic, Katarina
Skrha, Jan
Valensi, Paul
Ceriello, Antonio
Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
title Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
title_full Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
title_fullStr Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
title_full_unstemmed Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
title_short Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
title_sort report from the 3rd cardiovascular outcome trial (cvot) summit of the diabetes & cardiovascular disease (d&cvd) easd study group
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819256/
https://www.ncbi.nlm.nih.gov/pubmed/29458368
http://dx.doi.org/10.1186/s12933-018-0667-2
work_keys_str_mv AT schnelloliver reportfromthe3rdcardiovascularoutcometrialcvotsummitofthediabetescardiovasculardiseasedcvdeasdstudygroup
AT standleberhard reportfromthe3rdcardiovascularoutcometrialcvotsummitofthediabetescardiovasculardiseasedcvdeasdstudygroup
AT catrinoiudoina reportfromthe3rdcardiovascularoutcometrialcvotsummitofthediabetescardiovasculardiseasedcvdeasdstudygroup
AT genovesestefano reportfromthe3rdcardiovascularoutcometrialcvotsummitofthediabetescardiovasculardiseasedcvdeasdstudygroup
AT lalicnebojsa reportfromthe3rdcardiovascularoutcometrialcvotsummitofthediabetescardiovasculardiseasedcvdeasdstudygroup
AT lalickatarina reportfromthe3rdcardiovascularoutcometrialcvotsummitofthediabetescardiovasculardiseasedcvdeasdstudygroup
AT skrhajan reportfromthe3rdcardiovascularoutcometrialcvotsummitofthediabetescardiovasculardiseasedcvdeasdstudygroup
AT valensipaul reportfromthe3rdcardiovascularoutcometrialcvotsummitofthediabetescardiovasculardiseasedcvdeasdstudygroup
AT cerielloantonio reportfromthe3rdcardiovascularoutcometrialcvotsummitofthediabetescardiovasculardiseasedcvdeasdstudygroup